[1]吴丹丹,倪 萍,孙 更,等.eIF4E在CXCL12诱导的胃癌转移中的作用和机制[J].南京师大学报(自然科学版),2015,38(02):93.
　Wu Dandan,Ni Ping,Sun Geng,et al.eIF4E Promotes CXCL12 Induced Metastasis of Gastric Cancer[J].Journal of Nanjing Normal University(Natural Science Edition),2015,38(02):93.
点击复制

eIF4E在CXCL12诱导的胃癌转移中的作用和机制()
分享到：

《南京师大学报》（自然科学版）[ISSN:1001-4616/CN:32-1239/N]

卷:
第38卷
期数:
2015年02期
页码:
93
栏目:
生命科学
出版日期:
2015-06-30

文章信息/Info

Title:
eIF4E Promotes CXCL12 Induced Metastasis of Gastric Cancer
作者:
吴丹丹; 倪 萍; 孙 更; 何文萍; 翟溯澜; 李 萍; 邹美娟; 王雪融
南京医科大学基础医学院药理学系,江苏 南京 210029
Author(s):
Wu Dandan; Ni Ping; Sun Geng; He Wenping; Zhai Sulan; Li Ping; Zou Meijuan; Wang Xuerong
Department of Pharmacology,School of Medicine,Nanjing Medical University,Nanjing 210029,China
关键词:
CXCL12; eIF4E; 形态学改变; 迁移; 胃癌; MMP9
Keywords:
CXCL12; eIF4E; morphological changes; migration; gastric cancer; MMP9
分类号:
R739.91
文献标志码:
A
摘要:
探讨eIF4E在CXCL12诱导胃癌细胞形态学改变和迁移中的作用和机制. 在胃癌细胞株(SGC7901,MGC803)上给予CXCL12处理,显微镜下观察细胞形态的改变; 通过transwell实验检测CXCL12对胃癌细胞迁移能力的影响; 在SGC7901上给予CXCL12处理,用Western blot检测eIF4E磷酸化和总蛋白水平的变化; 用脂质体转染eIF4E的小干扰RNA,检测eIF4E对胃癌细胞形态学和迁移的影响; 以及用qRT-PCR检测与肿瘤侵袭转移密切相关的因子MMP9的mRNA水平的表达. 结果显示,给予CXCL12处理,胃癌细胞形态由上皮表型向长梭形的间叶样表型转变,细胞的迁移能力提高. 在相同浓度的CXCL12处理情况下,转染eIF4E siRNA抑制eIF4E的表达,可抑制CXCL12诱导的细胞的形态学改变和迁移能力. 另外,CXCL12引起与肿瘤转移密切相关因子MMP9的mRNA水平的表达升高,而用siRNA抑制eIF4E的表达,可下调MMP9的mRNA表达水平. 结论:CXCL12激活了eIF4E,阻抑eIF4E的表达抑制CXCL12诱导的形态学改变和细胞迁移,其作用机制可能与上调MMP9的表达有关.
Abstract:
To study of eIF4E in CXCL12 induced morphological changes and migration mechanism in gastric cancer cells. In gastric cancer cell lines(SGC7901,MGC803),cell morphological changes with CXCL12 treatment were observed under microscopy. The effect of CXCL12 on gastric cancer cell migration was determined by transwell assay. Western blot anlaysis was used to detect the eIF4E phosphorylation and total protein levels in SGC7901 treated with CXCL12. MMP9 mRNA expression was determined by qRT-PCR assay. Results show that,CXCL12 induced gastric cancer cells from epithelial morphology to mesenchymal morphology as well as increased migration. Morphological changes and migratory capacity induced by CXCL12 were inhibited by eIF4E siRNA transfection in SGC7901 cells. In addition,CXCL12 induced upregulation of MMP9 mRNA level. Conclusion:eIF4E is involved in CXCL12 induced the morphological changes and cell migration of gastric cancer cells possibility through upregulation of MMP9.

参考文献/References:

[1] International Agency For Research on Cancer. GLOBOCAN 2012:Estimated incidence,mortality and revalence worldwide in 2012[EB/OL]. [2014-10-25]http://globocan.iarc.fr/old/FactSheets/cancers/stomach-new.asp.
[2]Milne A N,Carneiro F,O’Morain C,et al. Nature meets nurture:molecular genetics of gastric cancer[J]. Hum Genet,2009,126(5):615-628.
[3]Orditura M,De Vita F,Muto P,et al. Adjuvant chemoradiotherapy in patients with stage Ⅲ or Ⅳ radically resected gastric cancer:a pilot study[J]. Arch Surg,2010,145(3):233-238.
[4]Lee H J,Kim S W,Kim H Y,et al. Chemokine receptor CXCR4 expression,function,and clinical implications in gastric cancer[J]. Int J Oncol,2009,34(2):473-480.
[5]Sun X,Cheng G,Hao M,et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression[J]. Cancer Metastasis Rev,2010,29(4):709-722.
[6]Teicher B A,Fricker S P. CXCL12(SDF-1)/CXCR4 pathway in cancer[J]. Clin Cancer Res,2010,16(11):2 927-2 931.
[7]Ying J,Xu Q,Zhang G,et al. The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis[J]. Med Oncol,2012,29(3):1 716-1 722.
[8]Yasumoto K,Koizumi K,Kawashima A,et al. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer[J]. Cancer Res,2006,66(4):2 181-2 187.
[9]De Benedetti A,Graff J R. eIF4E expression and its role in malignancies and metastases[J]. Oncogene,2004,23(18):3 189-3 199.
[10]Martineau Y,Azar R,Bousquet C,et al. Anti-oncogenic potential of the eIF4E-binding proteins[J]. Oncogene,2013,32(6):671-677.
[11]Graff J R,Konicek B W,Carter J H,et al. Targeting the eukaryotic translation initiation factor 4E for cancer therapy[J]. Cancer Res,2008,68(3):631-634.
[12]Thumma S C,Kratzke R A. Translational control:a target for cancer therapy[J]. Cancer Lett,2007,258(1):1-8.
[13]Ma Z,Zhu L,Luo X,et al. Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells[J]. Cancer Biol Ther,2012,13(11):1 009-1 017.
[14]Mathis J M,Williams B J,Sibley D A,et al. Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control[J]. J Gene Med,2006,8(9):1 105-1 120.
[15]Nowak D E,Tian B,Jamaluddin M,et al. RelA Ser276 phosphorylation is required for activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes[J]. Mol Cell Biol,2008,28(11):3 623-3 638.
[16]Chen G,Chen S M,Wang X,et al. Inhibition of chemokine(CXC motif)ligand 12/chemokine(CXC motif)receptor 4 axis(CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin(mTOR)pathway in human gastric carcinoma cells[J]. J Biol Chem,2012,287(15):12 132-12 141.
[17]Hashimoto I,Koizumi K,Tatematsu M,et al. Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells[J]. Eur J Cancer,2008,44(7):1 022-1 029.
[18]Monterrubio M,Mellado M,Carrera A C,et al. PI3Kgamma activation by CXCL12 regulates tumor cell adhesion and invasion[J]. Biochem Biophys Res Commun,2009,388(2):199-204.
[19]Sampieri C L,de la P S,Ochoa-Lara M,et al. Expression of matrix metalloproteinases 2 and 9 in human gastric cancer and superficial gastritis[J]. World J Gastroenterol,2010,16(12):1 500-1 505.
[20]Balkwill F R. The chemokine system and cancer[J]. J Pathol,2012,226(2):148-157.

相似文献/References:

[1]李 敏,谌 茜,马 倬,等.eIF4E 在非小细胞肺癌耐药性中的作用[J].南京师大学报(自然科学版),2014,37(02):91.
　Li Min,Chen Xi,Ma Zhuo,et al.eIF4E Promotes Drug Resistance in Non-small Cell Lung Carcinoma[J].Journal of Nanjing Normal University(Natural Science Edition),2014,37(02):91.

备注/Memo

备注/Memo:
收稿日期:2014-12-15.
基金项目:国家自然科学基金(81473241、81102458、811172004)、基础医学院优势学科、校引进人才启动基金.
通讯联系人:王雪融,博士,教授,研究方向:肿瘤药理. E-mail:wangxrwn@hotmail. Com
更新日期/Last Update: 2015-06-30